Geode Capital Management
ABVC icon

Geode Capital Management’s ABVC BioPharma ABVC Stock Holding History

Geode Capital Management’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
221,169
+18,804
+9% +$31.1K ﹤0.01% 3884
2025
Q4 		$431K Buy
202,365
+14,553
+8% +$39K ﹤0.01% 3642
2025
Q3 		$571K Buy
187,812
+77,313
+70% +$237K ﹤0.01% 3570
2025
Q2 		$246K Buy
110,499
+6,017
+6% +$8.19K ﹤0.01% 3805
2025
Q1 		$111K Buy
104,482
+25,197
+32% +$15.3K ﹤0.01% 4007
2024
Q4 		$46.8K Buy
79,285
+7,678
+11% +$4.28K ﹤0.01% 4253
2024
Q3 		$48.9K Buy
71,607
+16,382
+30% +$11.8K ﹤0.01% 4270
2024
Q2 		$42.7K Buy
55,225
+33,225
+151% +$34.1K ﹤0.01% 4311
2024
Q1 		$28.8K Buy
22,000
+2,520
+13% +$3.27K ﹤0.01% 4426
2023
Q4 		$22.6K Hold
19,480
– – ﹤0.01% 4496
2023
Q3 		$20.3K Buy
19,480
+5,552
+40% +$13.4K ﹤0.01% 4623
2023
Q2 		$71K Hold
13,928
– – ﹤0.01% 4434
2023
Q1 		$87.8K Hold
13,928
– – ﹤0.01% 4386
2022
Q4 		$87K Sell
13,928
-37
-0.3% -$273 ﹤0.01% 4442
2022
Q3 		$122K Buy
13,965
+8,973
+180% +$75.4K ﹤0.01% 4473
2022
Q2 		$52K Hold
4,992
– – ﹤0.01% 4765
2022
Q1 		$136K Hold
4,992
– – ﹤0.01% 4539
2021
Q4 		$169K Hold
4,992
– – ﹤0.01% 4553
2021
Q3 		$115K Buy
+4,992
New +$141K ﹤0.01% 4637

Other funds holding ABVC

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Geode Capital Management's ABVC Position: Q1 2026 in Review

Geode Capital Management increased its ABVC BioPharma (ABVC) stake by 9.3% in Q1 2026, buying an estimated $31.1K and bringing the position to 221,169 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3884.

Geode Capital Management first reported a position in ABVC in Q3 2021 and has held it in 19 quarters since. The position peaked at $571K in Q3 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

  • Geode Capital Management held 221,169 shares of ABVC BioPharma worth $215K as of Q1 2026.
  • Geode Capital Management bought 18,804 ABVC BioPharma shares in Q1 2026, an estimated $31.1K.
  • ABVC BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3884 holding.
  • Geode Capital Management first reported a position in ABVC BioPharma in Q3 2021 and has held it in 19 quarters since.
  • Geode Capital Management's ABVC BioPharma position peaked at $571K in Q3 2025.
  • 13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.